KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Announces Launch of RESPONSE™ 5.5/6.0 Cannulated Screw System

OrthoPediatrics Corp. Announces Launch of RESPONSE™ 5.5/6.0 Cannulated Screw System

WARSAW, Ind., April 20, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced the release of its new Cannulated Screw System for the RESPONSE™ Scoliosis portfolio. The RESPONSE 5.5/6.0 Cannulated Screw system is a complete portfolio of instruments and implants and represents the Company’s 47th surgical system and it’s continued commitment to leading innovation in pediatric orthopedics.

Greg Odle, President of OrthoPediatrics’ Scoliosis business, commented, “I’m incredibly proud of the team who led this development project! The launch of our RESPONSE 5.5/6.0 Cannulated Screw System is the latest addition to our Scoliosis franchise. The early feedback we have received from designing surgeons has been very positive – and we see this new system as an ideal solution for S1AI (S2 Alar-Iliac) screw placement.”

“S2 Alar fixation has become nearly universally adopted as the standard for pelvic fixation in neuromuscular spine deformity surgery,” said Dr. Brad Culotta, Orthopaedic Surgeon at the Baton Rouge Orthopaedic Clinic. “Now the instrumentation has evolved to allow surgeons to accurately and seamlessly place these screws. The OP cannulated system allows me to keep my desired path for screw placement from awl to tap to screw, saving me time and minimizing errors during instrumentation and screw insertion.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 47 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit .

Investor Contact

Philip Trip Taylor

Gilmartin Group



415-937-5406



EN
20/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in two upcoming investor conferences. Event: TD Cowen 46th Annual Health Care Conference Format: Fireside Chat Date: Tuesday, March 3, 2026Time: 1:10 pm ET Event: The Citizens Life Sciences Conference Format: Fireside Chat Date: Tuesday, March 10, 2026Time: 10:10 am ET An audio webcast of the ...

 PRESS RELEASE

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financ...

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Fina...

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results. Inv...

 PRESS RELEASE

OrthoPediatrics Announces Expanded Enabling Technology Market Opportun...

OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its partner, iotaMotion, has received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. The system is now cleared for ...

 PRESS RELEASE

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue fo...

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior yearInitiates guidance for record Adjusted EBITDA in 2026 WARSAW, Ind., Jan. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch